DongKoo Bio & Pharma

At a glance

DongKoo Bio & Pharma filed 45 disclosures in the last 12 months, including 19 5% holder and 3 buyback. The most recent key filing was on Oct 29: A major holder's stake rose from 37.18% to 37.18% (share lending).

Revenue for 2025 was ₩243B, down 2.6% on 2024. Operating margin was 3.8% against 5.1% a year earlier. Debt was 121% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩118B and operating loss of ₩4.6B.

The 2025 annual report lists 440 employees with an average tenure of 4.7 years and average pay of ₩56.5M, #1146 of 1,829 listed companies by average pay. Its 7 directors and auditors were paid ₩259.7M each on average. It paid ₩120 per common share in cash dividends, against ₩120 a year earlier (+0%). 조용준 and related parties held 37.00% at year end.

Of 3 recent 5%+ holder reports, 0 raised and 0 cut a stake; the largest stake reported was 37.18% on Oct 29.

From the 2025 annual report

Staff: 440 (271 men, 169 women), of whom 40 on fixed-term contracts. Total pay for the year: ₩24.8B. Directors and auditors: 7, paid ₩1.8B in total.

Dividends (common shares)

Largest shareholder

조용준 holds 28.35%; with 7 related parties the group holds 37.00% of common shares at year end (from 42.06% at the start of the year).

Individuals paid ₩500M or more

Auditor: 한영회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary

5%+ holder reports